Home » Stocks » RGNX

REGENXBIO Inc. (RGNX)

Stock Price: $37.68 USD -0.09 (-0.24%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $36.24 -1.44 (-3.82%) Jun 11, 7:10 PM
Market Cap 1.60B
Revenue (ttm) 155.81M
Net Income (ttm) -121.35M
Shares Out 41.82M
EPS (ttm) -3.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $37.68
Previous Close $37.77
Change ($) -0.09
Change (%) -0.24%
Day's Open 37.83
Day's Range 37.18 - 38.09
Day's Volume 128,372
52-Week Range 25.93 - 50.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ROCKVILLE, Md., June 9, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following June investor conferences, which will each be held in a virtual meeting fo...

3 days ago - PRNewsWire

Regenxbio Inc (NASDAQ: RGNX) has announced a safety update and additional positive interim data from its ongoing Phase 1/2 trial of RGX-121 to treat patients up to 5 years old diagnosed with Mucopolysac...

4 weeks ago - Benzinga

ROCKVILLE, Md., May 14, 2021 /PRNewswire/ -- RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related serious adverse events Biomarkers and measures of neurodevel...

4 weeks ago - PRNewsWire

ROCKVILLE, Md., May 6, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the following May investor conferences, which will each be held in a virtual meeting format: ...

1 month ago - PRNewsWire

Regenxbio (RGNX) delivered earnings and revenue surprises of -6.19% and -32.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

ROCKVILLE, Md., May 5, 2021 /PRNewswire/ -- Enrollment ongoing in ATMOSPHERE™, the first of two planned pivotal trials for the subretinal delivery of RGX-314 for the treatment of wet AMD Continued progr...

1 month ago - PRNewsWire

On Wednesday, May 05, Regenxbio (NASDAQ:RGNX) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

1 month ago - Benzinga

ROCKVILLE, Md., April 28, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 5, 2021, at 4:30 p.m.

1 month ago - PRNewsWire

ROCKVILLE, Md., April 27, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that four oral and nine poster presentations will be presented at the American Society of Gene and Cell Thera...

1 month ago - PRNewsWire

ROCKVILLE, Md., April 21, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that Curran M.

1 month ago - PRNewsWire

ROCKVILLE, Md., April 14, 2021 /PRNewswire/ -- First patient dosed at third dose level in ongoing trial of RGX-121, a one-time gene therapy for MPS II; total of nine patients have been dosed at four lea...

1 month ago - PRNewsWire

IHG, NNN, PRMW, RGNX, and WW have been added to the Zacks Rank #5 (Strong Sell) List on March 24, 2021

Other stocks mentioned: IHG, NNN, PRMW, WW
2 months ago - Zacks Investment Research

Regenxbio (RGNX) delivered earnings and revenue surprises of -211.71% and -83.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Regenxbio (NASDAQ:RGNX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 72.22% over the past year to ($1.24), which missed the est...

3 months ago - Benzinga

ROCKVILLE, Md., March 1, 2021 /PRNewswire/ -- Pivotal program for subretinal delivery of RGX-314 for the treatment of wet AMD is active and enrolling patients; expected to support BLA filing in 2024 Pha...

3 months ago - PRNewsWire

ROCKVILLE, Md., Feb. 24, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following March investor conferences, which will each be held in a virtual meeting ...

3 months ago - PRNewsWire

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Regenxbio Inc (NASDAQ: RGNX) has reported additional interim data from Cohorts 4 and 5 of its Phase 1/2a trial evaluating RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) and ...

3 months ago - Benzinga

ROCKVILLE, Md., Feb. 16, 2021 /PRNewswire/ -- RGX-314 using subretinal delivery continues to be generally well-tolerated at all dose levels Positive interim update from Cohorts 4 and 5 at 1.5 years afte...

3 months ago - PRNewsWire

ROCKVILLE, Md., Feb. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that additional positive interim data from a total of eight patients in Cohorts 1 and 2 of the ongoing Phase I/...

4 months ago - PRNewsWire

ROCKVILLE, Md., Feb. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that two oral presentations will be presented at the Angiogenesis, Exudation, and Degeneration 2021 conference ...

4 months ago - PRNewsWire

ROCKVILLE, Md., Feb. 1, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and nine poster presentations will be presented at the 17th Annual WORLDSymposium™, taking plac...

4 months ago - PRNewsWire

ROCKVILLE, Md., Jan. 12, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced underwritten public offering of 4,260,000 shares of its common stock a...

5 months ago - PRNewsWire

ROCKVILLE, Md., Jan. 11, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 11:40 a....

5 months ago - PRNewsWire

ROCKVILLE, Md., Jan. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the pricing of an underwritten public offering of 4,260,000 shares of its common stock at the price of $47.00 p...

5 months ago - PRNewsWire

Regenxbio launched a key study of its eye disease-targeting gene therapy, prompting RGNX stock to pop on Wednesday. It's also planning to test a gene therapy in muscular dystrophy.

5 months ago - Investors Business Daily

ROCKVILLE, Md., Jan. 6, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on...

5 months ago - PRNewsWire

REGENXBIO (RGNX) provided an update on the RGX-314 programs. Further, the company made an announcement of a new program, RGX-202, for the treatment of Duchenne Muscular Dystrophy

5 months ago - Zacks Investment Research

These three small-cap stocks all turned a profit last quarter and present ample growth potential at bargain prices.

Other stocks mentioned: KOP, ZYXI
5 months ago - The Motley Fool

ROCKVILLE, Md., Jan. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on the RGX-314 programs, including the announcement that the pivotal program for RGX-314 for the treat...

5 months ago - PRNewsWire

ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...

5 months ago - PRNewsWire

Back in 2019, the Zolgensma approval validated Regenxbio's NAV technology platform for gene delivery. Despite a slow start, Zolgensma recently hit $1B in cumulative sales. Regenxbio's organic pipeline i...

5 months ago - Seeking Alpha

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.

Other stocks mentioned: BMRN, DCPH, QURE
5 months ago - Zacks Investment Research

ROCKVILLE, Md., Dec. 10, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...

6 months ago - PRNewsWire

ROCKVILLE, Md., Dec. 8, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based o...

6 months ago - PRNewsWire

ROCKVILLE, Md., Dec. 1, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based o...

6 months ago - PRNewsWire

ROCKVILLE, Md., Nov. 23, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...

6 months ago - PRNewsWire

REGENXBIO, Inc. (RGNX) CEO Ken Mills on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Regenxbio (RGNX) delivered earnings and revenue surprises of 125.84% and 284.87%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Shares of Regenxbio (NASDAQ:RGNX) were flat after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 124.47% over the past year to $0.23, which beat the...

7 months ago - Benzinga

ROCKVILLE, Md., Oct. 28, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...

7 months ago - PRNewsWire

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

Other stocks mentioned: CBPO, GLPG, HRTX, ILMN, IONS, LGND
7 months ago - InvestorPlace

Gene therapy - which aims to treat diseases by essentially inserting a gene into a patient’s cells rather than via drugs or surgery - was a hot trend in the biotech space, but investor interest in the s...

Other stocks mentioned: QURE, SRPT, VYGR
8 months ago - Forbes

ROCKVILLE, Md., Sept. 30, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based...

8 months ago - PRNewsWire

ROCKVILLE, Md., Sept. 25, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based...

8 months ago - PRNewsWire

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty c...

8 months ago - PRNewsWire

Regenxbio: More Robust Data For Wet AMD

Other stocks mentioned: AMD
8 months ago - Seeking Alpha

ROCKVILLE, Md., Sept. 9, 2020 /PRNewswire/ -- REGENXBIO Inc.

9 months ago - PRNewsWire

ROCKVILLE, Md., Aug. 25, 2020 /PRNewswire/ -- REGENXBIO Inc.

9 months ago - PRNewsWire

REGENXBIO's (RGNX) CEO Ken Mills on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It i... [Read more...]

Industry
Biotechnology
IPO Date
Sep 17, 2015
CEO
Kenneth Mills
Employees
306
Stock Exchange
NASDAQ
Ticker Symbol
RGNX
Full Company Profile

Financial Performance

In 2020, REGENXBIO Inc.'s revenue was $154.57 million, an increase of 338.70% compared to the previous year's $35.23 million. Losses were -$111.25 million, 17.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for REGENXBIO Inc. stock is "Buy." The 12-month stock price forecast is 64.38, which is an increase of 70.86% from the latest price.

Price Target
$64.38
(70.86% upside)
Analyst Consensus: Buy